- Report
- November 2024
- 70 Pages
Global
From €5679EUR$5,950USD£4,758GBP
- Report
- October 2024
- 100 Pages
Global
From €5679EUR$5,950USD£4,758GBP
- Report
- February 2025
- 406 Pages
Global
From €5201EUR$5,450USD£4,358GBP
- Report
- March 2025
- 250 Pages
Global
From €4285EUR$4,490USD£3,590GBP
- Report
- February 2025
- 200 Pages
Global
From €4285EUR$4,490USD£3,590GBP
- Report
- May 2024
- 139 Pages
Global
From €6203EUR$6,499USD£5,197GBP
- Report
- August 2024
- 146 Pages
Global
From €2862EUR$2,999USD£2,398GBP
- Report
- February 2025
- 144 Pages
Global
From €2862EUR$2,999USD£2,398GBP
- Report
- May 2024
- 133 Pages
Global
From €6203EUR$6,499USD£5,197GBP
- Report
- May 2024
- 132 Pages
Global
From €6203EUR$6,499USD£5,197GBP
- Report
- May 2024
- 129 Pages
Global
From €6203EUR$6,499USD£5,197GBP
- Report
- October 2024
- 207 Pages
Global
From €7587EUR$7,950USD£6,357GBP
- Report
- November 2024
- 97 Pages
Global
From €7587EUR$7,950USD£6,357GBP
- Report
- June 2024
- 206 Pages
Global
From €7587EUR$7,950USD£6,357GBP
- Drug Pipelines
- April 2024
- 40 Pages
Global
From €1193EUR$1,250USD£1,000GBP
- Clinical Trials
- April 2024
- 40 Pages
Global
From €1193EUR$1,250USD£1,000GBP
- Report
- February 2025
- 182 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- April 2024
- 180 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- May 2022
- 330 Pages
Global
From €2863EUR$3,000USD£2,399GBP
- Report
- February 2022
- 360 Pages
United States
From €3436EUR$3,600USD£2,879GBP

Rituxan (rituximab) is a monoclonal antibody used to treat a variety of immune disorders, including non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and granulomatosis with polyangiitis. It is used in combination with other drugs to treat these conditions. Rituxan works by targeting and destroying B-cells, which are a type of white blood cell involved in the body's immune response.
Rituxan is a biologic drug, meaning it is made from living cells. It is administered intravenously and is typically given in two doses, two weeks apart. The drug has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of certain immune disorders.
Rituxan is a widely used drug in the immune disorders market. It is one of the most prescribed drugs for the treatment of non-Hodgkin's lymphoma and rheumatoid arthritis. It is also used off-label to treat other conditions, such as systemic lupus erythematosus.
Some companies in the Rituxan market include Genentech, Biogen, and Roche. Show Less Read more